Assenagon Asset Management S.A. Sells 782 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Assenagon Asset Management S.A. lowered its position in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) by 17.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 3,701 shares of the company’s stock after selling 782 shares during the period. Assenagon Asset Management S.A.’s holdings in Axsome Therapeutics were worth $313,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in AXSM. Northwestern Mutual Wealth Management Co. purchased a new stake in shares of Axsome Therapeutics during the second quarter valued at $27,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Axsome Therapeutics in the second quarter worth about $47,000. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Axsome Therapeutics by 22.4% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,736 shares of the company’s stock worth $156,000 after purchasing an additional 318 shares during the last quarter. Moors & Cabot Inc. acquired a new stake in shares of Axsome Therapeutics during the third quarter worth about $200,000. Finally, Whalen Wealth Management Inc. purchased a new stake in Axsome Therapeutics in the third quarter valued at approximately $236,000. Hedge funds and other institutional investors own 81.49% of the company’s stock.

Axsome Therapeutics Trading Down 0.8 %

NASDAQ:AXSM opened at $103.11 on Friday. The firm has a market capitalization of $5.00 billion, a P/E ratio of -15.79 and a beta of 1.04. The business has a 50 day simple moving average of $92.64 and a 200 day simple moving average of $90.09. The company has a debt-to-equity ratio of 1.97, a current ratio of 2.44 and a quick ratio of 2.37. Axsome Therapeutics, Inc. has a 12-month low of $64.11 and a 12-month high of $105.00.

Axsome Therapeutics (NASDAQ:AXSM) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($1.34) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.38) by $0.04. The company had revenue of $104.76 million during the quarter, compared to analyst estimates of $98.71 million. Axsome Therapeutics had a negative return on equity of 158.36% and a negative net margin of 91.87%. During the same quarter in the previous year, the firm posted ($1.32) EPS. Equities research analysts predict that Axsome Therapeutics, Inc. will post -4.73 EPS for the current year.

Analyst Ratings Changes

Several research analysts recently issued reports on the stock. Truist Financial raised their target price on shares of Axsome Therapeutics from $150.00 to $180.00 and gave the stock a “buy” rating in a report on Monday, January 13th. William Blair reissued an “outperform” rating on shares of Axsome Therapeutics in a report on Friday. Robert W. Baird raised their target price on Axsome Therapeutics from $112.00 to $116.00 and gave the stock an “outperform” rating in a report on Wednesday, November 13th. HC Wainwright reiterated a “buy” rating and set a $180.00 price target on shares of Axsome Therapeutics in a research report on Tuesday, January 21st. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $121.00 price objective on shares of Axsome Therapeutics in a research report on Thursday, December 12th. One research analyst has rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Axsome Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $130.69.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.